Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Surgeon General
  • Cigna’s ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

TRENDING TOPICS:

  • Surgeon General
  • Cigna's ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Jan 4 2024

Full Issue

Viewpoints: New Antibiotic Is Reason To Cheer, But Costs Could Sink It; Stop Pretending Covid Isn't A Problem

Editorial writers weigh in on these topics and others.

Nature: A New Class Of Antibiotics Is Cause For Cautious Celebration — But The Economics Must Be Fixed

Two studies published on January 3 in Nature report a new class of drug candidates for tackling A. baumannii infections. One of these compounds has already made it into clinical trials, but it is still a long way from being approved for clinical use. The obstacles for developing such compounds are not just scientific: the economic incentives are insufficient for many companies to take the risk. As the threat of resistance grows, the international community must do more to shepherd promising drugs from bench to bedside. (1/3)

Los Angeles Times: The U.S. Is Facing The Biggest Covid Wave Since Omicron. Why Are We Still Playing Make-Believe?

The pandemic is far from over, as evidenced by the rapid rise to global dominance of the JN.1 variant of SARS-CoV-2. This variant is a derivative of BA.2.86, the only other strain that has carried more than 30 new mutations in the spike protein since Omicron first came on the scene more than two years ago. This should have warranted designation by the World Health Organization as a variant of concern with a Greek letter, such as Pi. (Eric J. Topol, 1/4)

Dallas Morning News: We Can Stop Hospital Monopolies From Driving Up Costs For Texas

It is a tough time for most Americans. We’re experiencing the effects of staggering inflation across all areas of our daily lives. Not only have our grocery bills increased, medical costs are soaring. There are many things that our congressional members should be focusing on to provide more financial stability and freedom for American consumers. (Genevieve Collins, 1/4)

Stat: Why Psychiatrists Like Me Stop Taking Insurance 

“I’m sorry, but I’m unable to take on new patients at this time.” I’ve said that line hundreds of times in the 15 years since I started my solo private practice in psychiatry. I feel terrible each time I say it. Someone on the other end of the phone is suffering and has taken the difficult step to call for help — probably multiple calls, given the longstanding shortage of psychiatrists — and yet I added to their hopelessness. (Andrew Popper, 1/4)

The Washington Post: Texas, Where Women Are Less Important Than A Fetus

Texas doesn’t care if pregnant women die. That comes as no surprise in the post-Dobbs abortion landscape. But it’s worth noting when the state’s unceasing cruelty is aided and abetted by federal judges. (Ruth Marcus, 1/3)

The New York Times: Millions Die Of Malaria With Miracle Drugs At Hand

In late October a large-scale pilot rollout of the malaria vaccine RTS,S in parts of Africa by the World Health Organization was shown to have reduced child mortality in by 13 percent over four years, Science reported. It was so astonishing that mortality reduction in one disease could reshape the prospects of all childhood deaths that the epidemiologist who led the program said she expected gasps in the audience when the news was announced. (David Wallace-Wells, 1/3)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF